Arctic Vision closes USD32m Series A round led by Morningside
Arctic Vision recently announced that it has reached agreement on a 32 million US dollars Series A round of financing led by Morningside Venture Capital.
Arctic Vision (Jimu Bio) recently announced that it has reached agreement on a 32 million US dollars Series A round of financing led by Morningside Venture Capital.
Former incubation investor Nanfung Life Sciences and Pivotal BioVenture Partners continued to make additional investments. The proceeds will be used to advance the clinical trials of the ARVN001 product.
Arctic Vision is a drug development company that has entered clinical stage to address the unmet clinical needs of ophthalmic diseases. The company is committed to becoming a leading ophthalmic enterprise in China.
Starting with the product introduction model, Arctic Vision has established a product pipeline that covers a comprehensive range of ophthalmic diseases.
The company is gradually expanding the product portfolio to include global interests through continuous product introduction and the development of an in-house drug development platform.